SCARNA16: SCARNA16 is a small Cajal body-specific RNA (scaRNA) that has been shown to be involved in RNA processing [PMC8845156]. In a study investigating the expression pattern of SCARNA16 in hepatocellular carcinoma (HCC), it was found that SCARNA16 expression was significantly lower in HCC cell lines and clinical HCC tissues compared to normal hepatocyte cells [PMC8845156]. The down-regulation of SCARNA16 was found to be independently associated with a higher risk of tumor relapse and poor survival outcomes in HCC patients [PMC8845156]. Additionally, low expression of SCARNA16 was associated with more advanced clinical characteristics, such as larger tumor size, vessel carcinoma embolus, capsular invasion, and severe TNM stages [PMC8845156]. The study also demonstrated that SCARNA16 expression was not significantly influenced by the liver disease background or HBV infection [PMC8845156]. Furthermore, the study suggested that SCARNA16 could serve as a potential biomarker for HCC due to its decreased expression pattern in both cell lines and clinical specimens [PMC8845156]. However, further research is needed to elucidate the specific mechanism of SCARNA16 in HCC tumorigenesis and validate these findings with multicentric clinical data [PMC8845156][PMC9826665].